Release Date: August 30, 2019

Target Audience

This activity is for clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals. 

Learning Objectives

After completing this activity, participants should be better able to:

• Assess best available evidence regarding treatment of indolent and aggressive hematologic malignancies
• Evaluate the clinical implications of emerging data regarding non-Hodgkin lymphoma (NHL) transplant approaches
• Plan strategies to address complicated NHL transplant cases

Method of Participation

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through September 30, 2020.

Continuing Education

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

Faculty Disclosures

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Nathan Fowler, MD
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Advisory Board: AbbVie Inc., Celgene Corporation, Janssen, F. Hoffman-La Roche AG, TG Therapeutics, Inc.
Grants/Research Support: AbbVie Inc., Celgene Corporation, Janssen, F. Hoffman-La Roche AG, TG Therapeutics, Inc.

Julie Vose, MD, MBA
Professor and Chief
Division of Oncology & Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Consulting Fees: AbbVie, Inc.; Acerta Pharma LLC/AstraZeneca; BeiGene; Epizyme, Inc.; F. Hoffman-La Roche AG; Janssen/Pharmacyclics; Karyopharm Therapeutics; Kite Pharma; Legend Biotech; Nordic Nanovector ASA; Novartis; Sandoz Inc.; Vaniam Group; Verastem Oncology
Grants/Research Support: Acerta Pharma LLC; Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Celgene Corporation; Incyte Corporation; Kite Pharma; Merck & Co.; Novartis; Seattle Genetics, Inc.

Support

Educational grant support provided by AstraZeneca, Bayer Healthcare Pharmaceuticals, Celgene Corporation, and Gilead Sciences, Inc.

Technical Requirements

This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.